Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rapamycin - Effects on Alzheimer's and Cognitive Health (REACH)

NCT04629495 is registered in ClinicalTrials.gov with The University of Texas Health Science Center at San Antonio as lead sponsor.

NCT NCT04629495
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04629495 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rapamycin - Effects on Alzheimer's and Cognitive Health (REACH)
Lead sponsor
The University of Texas Health Science Center at San Antonio
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 11, 2021
Completion date
March 5, 2027
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, mild cognitive impairment